SRD5A1 and neoplasm: Luo and colleagues [7] detected no significant difference in the SRD5A1 mRNA level between tumor samples and BPH or normal samples, although Thomas et al. [8] found greater SRD5A1 immunostaining in tumor samples than they found in BPH samples.